View in EDS

Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus.

Saved in:
Bibliographic Details
Title: Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus.
Authors: Chang, Li-Hsin1 (AUTHOR), Chang, Ting-Ting2,3 (AUTHOR), Chu, Chia-Huei4,5 (AUTHOR), Huang, Chin-Chou2,3,6 (AUTHOR), Lin, Liang-Yu1,7,8 (AUTHOR) linly@vghtpe.gov.tw
Source: Clinica Chimica Acta. May2024, Vol. 558, pN.PAG-N.PAG. 1p.
Subjects: Tumor necrosis factor receptors, Type 2 diabetes, Glomerular filtration rate, Tumor necrosis factors, Diabetic nephropathies, Kidney physiology
Abstract: • sTNFR1 represents as a membrane-bound form or as a soluble form, which induce the release of chemokines, adhesion molecules, or apoptosis of targeted cells. • Increased sTNFR1 are associated with declining kidney function and occur during end-stage renal disease in diabetic kidney disease. • Predictability of sTNFR1 for renal outcomes is similar to UACR plus eGFR levels in T2DM. Urinary albumin-creatinine ratio (UACR) and estimated glomerular filtration rates (eGFR) help predict worsening diabetic kidney disease (DKD) but have their limitations. Soluble tumor necrosis factor receptor type 1 (sTNFR1) is a biomarker of DKD. The predictive abilities of sTNFR1 and UACR plus eGFR have not been compared. This prospective cohort study included patients with type 2 diabetes (T2D) to identify the risk factors of worsening DKD. Renal events were defined as > 30 % loss in eGFR based on consecutive tests after 6 months. The associations of sTNFR1, UACR, and eGFR levels and the risks of renal events were tested using a Cox regression model and the area under the curve (AUC) was compared between sTNFR1 levels and UACR plus eGFR using receiver-operating characteristic (ROC) analysis. The accuracy of stratification was evaluated using Kaplan–Meier analysis. Levels of sTNFR1 and UACR were associated with risks of > 30 % decline in eGFR after adjusting for relevant factors. The association between sTNFR1 levels and renal outcomes was independent of UACR and eGFR at baseline. The AUC of sTNFR1 level was comparable with that of combined UACR and eGFR (0.73 vs. 0.71, respectively, p = 0.72) and the results persisted for quartile groups of sTNFR1 and risk categories of Kidney Disease: Improving Global Outcomes (KDIGO) (0.70 vs. 0.71, respectively, p = 0.84). Both stratifications by sTNFR1 levels and KDIGO were accurate. sTNFR1 could be an alternative marker for identifying patients with diabetes at risk of declining renal function. [ABSTRACT FROM AUTHOR]
Copyright of Clinica Chimica Acta is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:• sTNFR1 represents as a membrane-bound form or as a soluble form, which induce the release of chemokines, adhesion molecules, or apoptosis of targeted cells. • Increased sTNFR1 are associated with declining kidney function and occur during end-stage renal disease in diabetic kidney disease. • Predictability of sTNFR1 for renal outcomes is similar to UACR plus eGFR levels in T2DM. Urinary albumin-creatinine ratio (UACR) and estimated glomerular filtration rates (eGFR) help predict worsening diabetic kidney disease (DKD) but have their limitations. Soluble tumor necrosis factor receptor type 1 (sTNFR1) is a biomarker of DKD. The predictive abilities of sTNFR1 and UACR plus eGFR have not been compared. This prospective cohort study included patients with type 2 diabetes (T2D) to identify the risk factors of worsening DKD. Renal events were defined as > 30 % loss in eGFR based on consecutive tests after 6 months. The associations of sTNFR1, UACR, and eGFR levels and the risks of renal events were tested using a Cox regression model and the area under the curve (AUC) was compared between sTNFR1 levels and UACR plus eGFR using receiver-operating characteristic (ROC) analysis. The accuracy of stratification was evaluated using Kaplan–Meier analysis. Levels of sTNFR1 and UACR were associated with risks of > 30 % decline in eGFR after adjusting for relevant factors. The association between sTNFR1 levels and renal outcomes was independent of UACR and eGFR at baseline. The AUC of sTNFR1 level was comparable with that of combined UACR and eGFR (0.73 vs. 0.71, respectively, p = 0.72) and the results persisted for quartile groups of sTNFR1 and risk categories of Kidney Disease: Improving Global Outcomes (KDIGO) (0.70 vs. 0.71, respectively, p = 0.84). Both stratifications by sTNFR1 levels and KDIGO were accurate. sTNFR1 could be an alternative marker for identifying patients with diabetes at risk of declining renal function. [ABSTRACT FROM AUTHOR]
ISSN:00098981
DOI:10.1016/j.cca.2024.117880